Zhang Zheng, Li Chen YuQi, Yang Yue, Li YeTong, Zheng XuMin, Jiao YuanYuan, Li WenGe
Department of Nephrology, China-Japan Friendship Hospital, Beijing, China.
Department of Nephrology, The Fourth Medical Center of Chinese PLA General Hospital, Beijing, China.
Genet Test Mol Biomarkers. 2024 Dec;28(12):467-473. doi: 10.1089/gtmb.2024.0330. Epub 2024 Dec 10.
IgA nephropathy (IgAN) is the most common primary glomerular disease. The renin-angiotensin system (RAS) plays an important role in the development of IgAN. Polymorphisms in genetic loci coding for the RAS may be associated with IgAN progression. We analyzed the M235T, A1166C, and A1675G polymorphisms in 297 IgAN patients, and analyzed their associations with clinical manifestations, pathological damage, effects of RAS-inhibitor treatment, and IgAN patient prognosis. In patients with the A1675G polymorphism, creatinine levels were significantly lower in those with the AG genotype than in those with the AA genotype ( = 0.023). However, this difference was not significant when creatinine levels were analyzed according to sex. Patients with endocapillary proliferation according to the Oxford Classification of IgAN were less likely to have the AG genotype than the AA genotype ( = 0.025). In IgAN patients treated with angiotensin-II-receptor blockers, 24-h urine protein levels were lower in patients with the AC genotype of A1166C than in those with the AA genotype at baseline and follow-up (Base = 0.013, 1 month = 0.0035, 3 months = 0.009). Cox regression analysis implied that the three gene polymorphisms were not independent risk factors for the prognosis of IgAN. The AG genotype of A1675G may confer protection against the development of IgAN, with a stronger protective effect observed in females. M235T, A1166C, and A1675G do not appear to be independent risk factors for IgAN.
IgA肾病(IgAN)是最常见的原发性肾小球疾病。肾素-血管紧张素系统(RAS)在IgAN的发展中起重要作用。编码RAS的基因座中的多态性可能与IgAN的进展相关。我们分析了297例IgAN患者的M235T、A1166C和A1675G多态性,并分析了它们与临床表现、病理损伤、RAS抑制剂治疗效果及IgAN患者预后的关联。在具有A1675G多态性的患者中,AG基因型患者的肌酐水平显著低于AA基因型患者(P = 0.023)。然而,按性别分析肌酐水平时,这种差异不显著。根据IgAN的牛津分类,有毛细血管内增生的患者比AA基因型患者更不易具有AG基因型(P = 0.025)。在接受血管紧张素II受体阻滞剂治疗的IgAN患者中,A1166C的AC基因型患者在基线和随访时的24小时尿蛋白水平低于AA基因型患者(基线时P = 0.013,1个月时P = 0.0035,3个月时P = 0.009)。Cox回归分析表明,这三种基因多态性不是IgAN预后的独立危险因素。A1675G的AG基因型可能对IgAN的发展具有保护作用,在女性中观察到更强的保护作用。M235T、A1166C和A1675G似乎不是IgAN的独立危险因素。